Cancer Patients Less Protected By One Shot Of Covid-19 Vacci
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Cancer patients are less protected against Covid-19 than other people after receiving one dose of the Pfizer-BioNTech vaccine, early findings from the first real-world study examining the issue suggest, which could leave patients vulnerable under vaccination strategies.

The study, looked at the degree of protection one dose of the Pfizer-BioNTech vaccine gave after three weeks in the 205 people recruited. When testing antibody responses in 205 volunteers, only 39% with solid cancers and 13% with blood cancer showed a response. In contrast, 97% of the people with no cancer showed an antibody response.

A second dose of the vaccine given after three weeks led to a dramatic improvement, with 95% of solid cancer patients showing detectable antibodies, the researchers reported. Based on the findings, the researcher, said she “would recommend an urgent review of the vaccine strategy for clinically extremely vulnerable groups.”

Professor Adrian Hayday, also from King’s College London, said the study shows the vaccine can clearly bring immense benefit to cancer patients too, but in most cases this is only after boosting, urging patients to be vaccinated and boosted quickly with their responses monitored carefully.

The U.K. is notable in spacing shots out by 12 weeks against manufacturer's guidelines. The approach was reluctantly endorsed by the World Health Organization. Findings from real-world studies have largely vindicated the approach, the researchers say.